Amarin Co. plc Stock Rating Lowered by HC Wainwright (AMRN)
Amarin Co. plc (NASDAQ:AMRN) was downgraded by investment analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a note issued to investors on Thursday, TheFlyOnTheWall.com reports.
Amarin Co. plc (NASDAQ:AMRN) traded down 62.95% during mid-day trading on Thursday, hitting $1.9153. 94,136,544 shares of the company’s stock traded hands. Amarin Co. plc has a 52 week low of $4.50 and a 52 week high of $12.96. The stock’s 50-day moving average is $6.47 and its 200-day moving average is $6.42. The company’s market cap is $330.6 million. Amarin Co. plc also saw some unusual options trading activity on Monday. Stock traders acquired 38,228 call options on the company. This represents an increase of 179% compared to the typical volume of 13,680 call options.
Amarin Co. plc (NASDAQ:AMRN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. Analysts expect that Amarin Co. plc will post $-1.39 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity downgraded shares of Amarin Co. plc from a “buy” rating to a “hold” rating in a research note to investors on Thursday. They now have a $3.00 price target on the stock, down previously from $10.00. They noted that the move was a valuation call. Separately, analysts at Jefferies Group downgraded shares of Amarin Co. plc to a “buy” rating in a research note to investors on Thursday. They now have a $4.00 price target on the stock, down previously from $20.00. Finally, analysts at JPMorgan Chase & Co. downgraded shares of Amarin Co. plc from an “overweight” rating to a “neutral” rating in a research note to investors on Thursday. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $9.88.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.